Association of the Preoperative Neutrophil-to-Lymphocyte Count Ratio and Platelet-to-Lymphocyte Count Ratio with Clinicopathological Characteristics in Patients with Papillary Thyroid Cancer

Sang Mi Kim1,*, Eun Heui Kim2,*, Bo Hyun Kim2,3, Jong Ho Kim2, Su Bin Park2, Yoon Jeong Nam2, Kang Hee Ahn2, Min Young Oh1, Won Jin Kim2, Yun Kyung Jeon2, Sang Soo Kim2, Yong Ki Kim4, In Ju Kim2

1Department of Internal Medicine, Dongeui Medical Center; 2Department of Internal Medicine, Pusan National University School of Medicine; 3Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine; 4Kim Yong Ki Internal Medicine Clinic, Busan, Korea

Background: Several inflammatory biomarkers, especially a high preoperative neutrophil-to-lymphocyte count ratio (NLR) and platelet-to-lymphocyte count ratio (PLR), are known to be indicator of poor prognosis in several cancers. However, very few studies have evaluated the significance of the NLR and PLR in papillary thyroid cancer (PTC). We evaluated the association of the preoperative NLR and PLR with clinicopathological characteristics in patients with PTC.

Methods: This study included 1,066 female patients who underwent total thyroidectomy for PTC. Patients were stratified into 4 quartiles by preoperative NLR and PLR. And the combination of preoperative NLR and PLR was calculated on the basis of data obtained value of tertile as follows: patients with both an elevated PLR and an elevated NLR were allocated a score of 2, and patients showing one or neither were allocated a score of 1 or 0, respectively.

Results: The preoperative NLR and PLR were significantly lower in patients aged ≥45 years and in patients with Hashimoto’s thyroiditis. The PLR was significantly higher in patients with tumor size >1 cm (P = 0.021). When the patients were categorized into the aforementioned four groups, the group with the higher preoperative PLR was found to have a significantly increased incidence of lateral lymph node metastasis (LNM) (P = 0.018). However, there are no significant association between the combination of preoperative NLR and PLR and prognostic factors in PTC patients.

Conclusion: These results suggest that a preoperative high PLR were significant associated with lateral LNM in female patients with PTC.

Keywords: Neutrophil-to-lymphocyte ratio; Platelet-to-lymphocyte ratio; Thyroid neoplasms; Prognosis

Received: 24 February 2015, Revised: 18 March 2015, Accepted: 23 June 2015
Corresponding author: Bo Hyun Kim
Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, 179 Gudeok-ro, Seo-gu, Busan 49241, Korea
Tel: +82-51-240-7678, Fax: +82-51-254-3237, E-mail: pons71@hanmail.net
*These authors contributed equally to this work.

Copyright © 2015 Korean Endocrine Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION

In cancer patients, variations in clinical outcomes are associated with the oncological characteristics of the tumor and host responses to systemic inflammation. In particular, systemic inflammatory responses in malignancies may arise from nonspecific events that are altered by neuroendocrine metabolism; these may include hematopoietic changes, endocrine hormones, and changes secondary to tumor hypoxia, necrosis, or local tissue damage [1].

The tumor microenvironment and the inflammatory response in particular play several important roles in a variety of cancer, by promoting tumor cell proliferation, survival, angiogenesis, invasion, and metastasis. This is achieved through the release of T lymphocytes, chemokines, activated cytokines, interleukin-6 (IL-6), tumor necrosis factor α, and C-reactive protein (CRP), leading to neutrophilia. Such dysregulation of the immune system and the response to hormones may alter the effect of chemotherapy [2-4].

Recent studies have shown that several biomarkers associated with the inflammatory response, especially CRP, the neutrophil-to-lymphocyte count ratio (NLR), and the platelet-to-lymphocyte count ratio (PLR), are predictors of a poor prognosis [3]. A high preoperative NLR is a poor prognostic marker in some cancers, including cholangiocarcinoma as well as lung, gastric, pancreatic, colorectal, and ovarian cancers [5-11], and a high preoperative PLR is associated with a poor prognosis in pancreatic and operable colorectal cancers [11,12]. However, only a few studies have evaluated the significance of the NLR and PLR in thyroid cancer [13,14], and, to the best of our knowledge, there has been no studies investigating the PLR in patients with papillary thyroid cancer (PTC).

In this study, we evaluated the association between the preoperative NLR and PLR and the clinicopathological characteristics of patients with PTC.

METHODS

We performed a retrospective chart review of 1,194 patients who underwent total thyroidectomy for PTC at Pusan National University Hospital between February 1, 2011 and May 31, 2013 to collect their clinical characteristics and demographic data.

Laboratory data were obtained from screening blood samples collected up to 2 weeks prior to total thyroidectomy, while thyroid-stimulating hormone (TSH) levels were measured before surgery. Complete blood counts, and automated differential counts were obtained 1 day before surgery. The NLR was calculated by dividing neutrophil count by the lymphocyte count; similarly, the PLR was calculated by dividing the platelet count by the lymphocyte count. Fasting morning blood samples were collected for these analyses.

Some earlier studies revealed that women in an immunocompromised state have higher neutrophil counts than men, probably because of sex hormones [15,16]. Accordingly, we surmised that there would be a gender-based difference in neutrophil counts in some pathologic conditions such as thyroid cancer. Additionally, it has been reported that gender influences clinicopathological features that predict the prognosis of PTC [17]. Therefore, we excluded male patients from the study (n=128), and investigated the association between the preoperative NLR and PLR and the clinicopathological features of 1,066 female patients with PTC. These female patients were reassigned into quartiles based on the preoperative NLR and PLR.

A previous study showed that the combined evaluation of the NLR and PLR was superior to the evaluation of the NLR or PLR alone as a predictive factor in patients with esophageal cancer [18]. Thus, we assumed that the combination of NLR and PLR was more likely to predict poor clinicopathological factors than the NLR or PLR alone in patients with PTC.

The patients were stratified into tertile groups based on the preoperative NLR and PLR. Then the combination of NLR and PLR was calculated on the basis of data obtained value of 3rd tertile as follows: patients with both an elevated PLR (>144.07) and an elevated NLR (>1.88) were allocated a score of 2, and patients showing one or neither were allocated a score of 1 or 0, respectively.

Central compartment neck dissections were routinely performed during total thyroidectomy; selective neck dissections were performed when node metastasis was suspected by ultrasonography or computed tomography findings, or upon positive cytological findings in samples obtained by preoperative fine needle aspiration from suspicious cervical neck lymph nodes.

Body mass index (BMI) was calculated as the weight in kilograms divided by the height in meters squared. Tumor size was determined according to the greatest diameter of the lesion, based on postoperative biopsy results. Patients were staged according to the TNM classification system of the American Joint Committee on Cancer [19]. The T stage was classified as 1/2 or 3/4, while the N stage was classified according to lymph node metastasis (LN, N0 vs. N1) and lateral LNM (N0+N1a vs. N1b).

We tested for Hashimoto’s thyroiditis, which was identified
by diffuse lymphocyte infiltration, and lymphoid follicular formation in postoperative biopsy samples. We used the Seeplex BRAF ACE detection kit (Seegene, Seoul, Korea) to detect the BRAF V600E mutation in tumor tissues after thyroidectomy.

Informed consent was obtained from all patients, prior to thyroidectomy. The study was approved by the Institutional Review Board at Pusan National University Hospital, Busan, Korea.

Statistical analysis
Statistical analyses were performed using SPSS version 21.0 (IBM Co., Armonk, NY, USA). The Student t test was used to evaluate the relationship between the preoperative NLR and PLR and the other clinicopathological characteristics of PTC. One-way analysis of variance and Pearson chi-square test were used to compare different quartiles. Among the continuous variables, NLR, PLR, TSH, and tumor size are expressed as the median and interquartile range (IQR) age, BMI, and the number of tumors are expressed as mean ± standard deviation. A P<0.05 was considered statistically significant.

RESULTS
A total of 1,066 female PTC patients were included in this analysis. Table 1 shows the relationships between the preoperative NLR and PLR values and the clinicopathological characteristics of PTC.

### Table 1. The Association between Preoperative NLR and PLR Values and the Clinicopathological Characteristics of Papillary Thyroid Cancer

| Characteristic                  | Patients, n (%) | NLR Median (IQR) | P value | PLR Median (IQR) | P value |
|---------------------------------|-----------------|------------------|---------|------------------|---------|
| **Age, yr**                     |                 |                  |         |                  |         |
| <45                             | 324 (30.4)      | 1.75 (1.03–2.31) | 0.001   | 135.60 (91.00–163.06) | <0.001  |
| ≥45                             | 742 (69.6)      | 1.52 (1.16–2.00) |         | 123.60 (99.32–151.42) |         |
| **Tumor size, cm**              |                 |                  |         |                  |         |
| ≤1                              | 774 (75.6)      | 1.59 (1.20–2.06) | 0.522   | 124.41 (103.13–155.09) | 0.021   |
| >1                              | 292 (27.4)      | 1.53 (1.22–2.12) |         | 129.17 (106.24–162.44) |         |
| **T stage**                     |                 |                  |         |                  |         |
| 1/2                             | 944 (88.6)      | 1.57 (1.21–2.08) | 0.370   | 125.62 (104.05–156.11) | 0.801   |
| 3/4                             | 122 (11.4)      | 1.63 (1.20–2.13) |         | 127.70 (97.84–156.75) |         |
| **LNM**                         |                 |                  |         |                  |         |
| N0                              | 432 (40.5)      | 1.57 (1.19–2.07) | 0.634   | 125.59 (103.28–154.50) | 0.765   |
| N1                              | 634 (59.5)      | 1.68 (1.34–2.24) |         | 132.10 (114.12–149.81) |         |
| **Multifocality**               |                 |                  |         |                  |         |
| Negative                        | 746 (70)        | 1.60 (1.23–2.11) | 0.483   | 126.06 (105.58–156.75) | 0.526   |
| Positive                        | 320 (30)        | 1.53 (1.16–2.04) |         | 126.50 (99.35–154.50) |         |
| **Hashimoto’s thyroiditis**     |                 |                  |         |                  |         |
| Negative                        | 940 (88.2)      | 1.58 (1.21–2.11) | 0.005   | 127.61 (104.89–157.38) | 0.039   |
| Positive                        | 126 (11.8)      | 1.52 (1.18–1.89) |         | 119.48 (94.02–147.48) |         |
| **ETE**                         |                 |                  |         |                  |         |
| Negative                        | 654 (61.4)      | 1.59 (1.20–2.08) | 0.185   | 124.31 (103.27–157.95) | 0.805   |
| Positive                        | 412 (38.6)      | 1.57 (1.22–2.10) |         | 128.09 (106.15–154.26) |         |
| **Lateral LNM**                 |                 |                  |         |                  |         |
| Negative                        | 1,001 (93.9)    | 1.57 (1.19–2.07) | 0.101   | 125.59 (103.28–156.72) | 0.316   |
| Positive                        | 65 (6.1)        | 1.68 (1.34–2.24) |         | 132.10 (114.38–148.46) |         |
| **LVI**                         |                 |                  |         |                  |         |
| Negative                        | 524/715 (73.3)  | 1.58 (1.21–2.04) | 0.155   | 126.96 (103.58–157.59) | 0.400   |
| Positive                        | 191/715 (26.7)  | 1.52 (1.13–2.22) |         | 130.18 (104.77–158.92) |         |
| **BRAF V600E mutation**         |                 |                  |         |                  |         |
| Negative                        | 383/1,003 (38.2)| 1.58 (1.17–2.08) | 0.896   | 125.96 (101.57–154.28) | 0.658   |
| Positive                        | 620/1,003 (61.8)| 1.57 (1.23–2.10) |         | 125.68 (103.93–156.72) |         |

Statistical significance was tested by the Student t test. NLR, neutrophil-to-lymphocyte count ratio; PLR, platelet-to-lymphocyte count ratio; IQR, interquartile range; LNM, lymph node metastasis; ETE, extrathyroidal extension; LVI, lymphovascular invasion.
tive NLR and PLR values, and the clinicopathological characteristics of PTC. The preoperative NLR and PLR were significantly lower in patients aged ≥45 years and in patients with Hashimoto’s thyroiditis. The PLR was significantly higher in patients with tumor size >1 cm; the median PLR was 139.89, with an IQR of 129.17 (vs. 132.41 with an IQR of 124.41 in

**Table 2. Comparisons of the Prevalence of Prognostic Factors between Preoperative NLR Quartile Groups**

| Variable          | Group 1          | Group 2          | Group 3          | Group 4          | P value |
|-------------------|------------------|------------------|------------------|------------------|---------|
| No. in quartile   | 266              | 266              | 266              | 268              |         |
| NLR, range        | 0.25–1.21        | 1.21–1.57        | 1.57–2.07        | 2.08–10.20       |         |
| Age, yr           | 51.99±10.64      | 50.72±11.09      | 48.96±11.17      | 49.16±11.78      | 0.005   |
| BMI, kg/m²        | 23.55±3.04       | 23.37±2.96       | 24.17±13.33      | 23.30±3.13       | 0.482   |
| Tumor size, cm    | 0.86±0.58        | 0.92±0.61        | 0.80±0.53        | 0.88±0.61        | 0.131   |
| TSH, mIU/L        | 1.45 (0.92–2.39) | 1.38 (0.84–2.26) | 1.33 (0.90–2.13) | 1.27 (0.84–2.04) | 0.245   |
| T stage 3/4, %    | 31 (11.7)        | 25 (9.4)         | 34 (12.8)        | 32 (11.9)        | 0.649   |
| LNM, %            | 166 (62.4)       | 157 (59.0)       | 153 (57.5)       | 158 (59.0)       | 0.700   |
| Lateral LNM, %    | 11 (4.1)         | 20 (7.5)         | 15 (5.6)         | 19 (7.1)         | 0.350   |
| Multifocality, %  | 90 (33.8)        | 81 (30.5)        | 76 (28.6)        | 73 (27.2)        | 0.374   |
| ETE, %            | 101 (38.0)       | 110 (41.4)       | 98 (36.8)        | 103 (38.4)       | 0.743   |
| LVI, %            | 57/187 (30.5)    | 43/171 (25.1)    | 32/179 (17.9)    | 59/178 (33.1)    | 0.006   |
| BRAF V600E mutation, % | 147/252 (58.3) | 163/248 (65.7) | 153/249 (61.4)  | 157/254 (61.8)  | 0.405   |

Values are expressed as mean±SD, median (interquartile range), or number (%). Statistical significance was tested by one-way analysis of variance, or the chi-square test.

NLR, neutrophil-to-lymphocyte count ratio; BMI, body mass index; TSH, thyroid-stimulating hormone; LNM, lymph node metastasis; ETE, extrathyroidal extension; LVI, lymphovascular invasion.

*The differences were only between quartile group 1 and quartile group 3 and 4 in post hoc analysis.

**Table 3. Comparisons of the Prevalence of Prognostic Factors between Preoperative PLR Quartile Groups**

| Variable          | Group 1          | Group 2          | Group 3          | Group 4          | P value |
|-------------------|------------------|------------------|------------------|------------------|---------|
| No. in quartile   | 266              | 266              | 266              | 268              |         |
| PLR, range        | 13.32–103.85     | 104.01–125.96    | 126.0–155.97     | 156.25–407.81    |         |
| Age, yr           | 52.93±10.62      | 49.56±11.36      | 48.96±11.36      | 49.16±11.78      | <0.001  |
| BMI, kg/m²        | 23.87±3.26       | 23.51±3.23       | 23.85±13.27      | 23.16±2.91       | 0.631   |
| Tumor size, cm    | 0.87±0.60        | 0.86±0.60        | 0.88±0.59        | 0.84±0.55        | 0.914   |
| TSH, mIU/L        | 1.37 (0.90–2.33) | 1.32 (0.78–2.10) | 1.42 (0.93–2.24) | 1.32 (0.87–2.18) | 0.212   |
| T stage 3/4, %    | 33 (12.4)        | 24 (9.0)         | 33 (12.4)        | 32 (11.9)        | 0.554   |
| LNM, %            | 159 (59.8)       | 154 (57.9)       | 166 (62.4)       | 155 (57.8)       | 0.675   |
| Lateral LNM, %    | 8 (3.0)          | 18 (6.8)         | 25 (9.4)         | 14 (5.2)         | 0.018   |
| Multifocality, %  | 90 (33.8)        | 70 (26.3)        | 82 (30.8)        | 78 (29.1)        | 0.287   |
| ETE, %            | 96 (36.1)        | 100 (37.6)       | 120 (45.1)       | 96 (35.8)        | 0.092   |
| LVI, %            | 46/177 (26.0)    | 43/168 (25.6)    | 52/182 (29.1)    | 49/188 (26.1)    | 0.865   |
| BRAF V600E mutation, % | 155/254 (61.0) | 156/249 (62.7) | 152/248 (61.3)  | 157/252 (62.3)  | 0.978   |

Values are expressed as mean±SD, median (interquartile range), or number (%). Statistical significance was tested by one-way analysis of variance, or the chi-square test.

PLR, platelet-to-lymphocyte count ratio; BMI, body mass index; TSH, thyroid-stimulating hormone; LNM, lymph node metastasis; ETE, extrathyroidal extension; LVI, lymphovascular invasion.

*The differences were significant only between quartile group 1 and quartile group 2, 3, and 4 in post hoc analysis.
patients with tumor size ≤1 cm; \( P=0.021 \). The preoperative NLR and PLR were not associated with multifocality, extrathyroidal extension (ETE), lateral LNM, lymphovascular invasion (LVI), the \( \text{BRAF V600E} \) mutation, tumor size, T stage, or LNM.

Patients were stratified by quartiles according to the preoperative NLR and PLR, and the prevalence of prognostic factors was compared between preoperative NLR and PLR quartiles (Tables 2, 3). Table 2 shows the relationships between clinicopathologic factors and NLR quartiles. The older patients had significant lower LNR values, but the differences were only between quartile 1 and quartile 3 and 4 in post hoc analysis. Significant differences were found between the NLR and LVI \( (P=0.006) \), but, there was not a meaningful correlation between NLR and LVI.

Table 3 showed that increasing preoperative PLR values from quartile 1 to quartile 3 were associated with increasing incidences of lateral LNM \( (P=0.018) \), with a positive correlation between the preoperative PLR from quartile 1 to quartile 3 \( (r=0.032, P=0.003, \text{data not shown}) \) and lateral LNM. However, patients in quartile 4 had a lower incidence of lateral LNM than patients in quartile 2 and 3. The older patients had significant lower PLR values, but the differences were significant only between quartile 1 and quartile 2, 3, and 4 in post hoc analysis. The preoperative PLR were not significantly associated with other clinicopathological factors (e.g., BMI, tumor size, TSH, T stage, LNM, multifocality, ETE, LVI, and the \( \text{BRAF V600E} \) mutation).

The higher value of combination of preoperative NLR and PLR were significantly associated with younger age in one way analysis of variance \( (P=0.004) \), but the differences were significant only between the score 0 and the score 2 (Table 4). There are no correlation between the combination of preoperative NLR and PLR and other prognostic factors (e.g., BMI, tumor size, TSH, T stage, LNM, lateral LNM, multifocality, ETE, LVI, and the \( \text{BRAF V600E} \) mutation).

**DISCUSSION**

Systemic inflammation has been reported to contribute to cancer development and progression, through the promotion of proliferation, survival, migration, and angiogenesis, as well as the suppression of antitumor immunity through the release of chemokines, especially regulatory T cells [20,21].

---

### Table 4. Relationships between Clinicopathological Characteristics and the Combination of Preoperative NLR and PLR in Papillary Thyroid Cancer Patients

| Characteristic                      | Score 0       | Score 1       | Score 2       | \( P \) value |
|-------------------------------------|---------------|---------------|---------------|---------------|
| No. in quartile                     | 334           | 517           | 215           |               |
| NLR (95% CI)                        | 1.23 (0.25–1.87) | 1.57 (0.57–5.09) | 2.50 (1.88–10.20) |               |
| PLR (95% CI)                        | 103.95 (13.32–143.82) | 125.43 (47.99–294.70) | 181.01 (144.07–407.81) |               |
| Age, yr (mean ± SD)                 | 51.58 ±11.36  | 50.09 ±10.95  | 48.33 ±11.47* | 0.004         |
| BMI, kg/m\(^2\) (mean ± SD)        | 24.20 ±11.91  | 23.34 ±3.17   | 23.28 ±3.07   | 0.178         |
| Tumor size, cm (mean ± SD)         | 0.85 ±0.57    | 0.86 ±0.59    | 0.88 ±0.60    | 0.876         |
| TSH, mIU/L (mean ± SD)             | 1.32 (0.79–2.33) | 1.43 (0.91–2.24) | 1.29 (0.86–2.12) | 0.507         |
| T stage 3/4, % (mean ± SD)         | 43 (12.9)     | 52 (10.1)     | 27 (12.6)     | 0.383         |
| LNM, % (mean ± SD)                 | 214 (64.1)    | 296 (57.3)    | 124 (57.7)    | 0.118         |
| Lateral LNM, % (mean ± SD)         | 19 (5.7)      | 34 (6.6)      | 12 (5.6)      | 0.817         |
| Multifocality, % (mean ± SD)       | 107 (32.0)    | 153 (29.6)    | 60 (27.9)     | 0.563         |
| ETE, % (mean ± SD)                 | 126 (37.7)    | 203 (39.3)    | 83 (38.6)     | 0.903         |
| LVI, % (mean ± SD)                 | 65/218 (29.8) | 82/343 (23.9) | 44/154 (28.6) | 0.256         |
| \( \text{BRAF V600E} \) mutation, % (mean ± SD) | 191/312 (61.2) | 305/488 (62.5) | 124/203 (61.1) | 0.909         |

Values are expressed as median (interquartile range), mean ± SD, or number (%). Statistical significance was tested by one-way analysis of variance, or the chi-square test.

NLR, neutrophil-to-lymphocyte count ratio; PLR, platelet-to-lymphocyte count ratio; BMI, body mass index; TSH, thyroid-stimulating hormone; LNM, lymph node metastasis; ETE, extrathyroidal extension; LVI, lymphovascular invasion.

\*The differences were significant only between the score 0 and the score 2.
The mechanism underlying the association of a high NLR with a poor cancer prognosis remains unknown. Cancers have been shown to secrete myeloid growth factors, such as granulocyte colony-stimulating factor, IL-1, IL-6, and tumor necrosis factor-alpha, which may result in tumor-related leukocytosis and neutrophilia [12]. Accordingly, neutrophils promote cancer progression and stimulate the tumor microenvironment by releasing tumor growth promoting factors, such as vascular endothelial growth factor [22,23], hepatocyte growth factor [24], IL-6 [25], IL-8 [26], matrix metalloproteinases [27], and elastases [28].

The exact mechanisms underlying the association between an elevated PLR values and the biological behavior of cancer cells remain unclear. One hypothesis is that megakaryocyte-mediated thrombocytosis may result from the release of proinflammatory mediators such as IL-1, IL-2, and IL-6 [29]. Moreover, a high PLR value may be considered an indicator of inflammation [20].

Several studies have reported that a high NLR may be associated with a poor prognosis of solid tumor cancers, including lung, gastric, pancreatic, ovarian, and colorectal cancers, in addition to colorectal liver metastases, and cholangiocarcinomas [5-10,30,31]. Moreover, the PLR has recently been identified as an independent prognostic factor in patients undergoing potentially curative resections for pancreatic and operable colorectal cancers [3,11]; the PLR is also associated with a poor prognosis in breast cancer patients [32]. The combination of preoperative NLR and PLR has been shown to be significantly associated with the risk of cervical stromal involvement in patients with endometrial cancer [33]. Thus, the preoperative NLR and/or PLR are independent prognostic factors for several malignancies.

Previous studies have demonstrated that neutrophil viability and counts were significantly higher in women than in men because of the effect of sex hormones [14]. Furthermore, another study showed that female patients had higher circulating neutrophil counts, lower lymphocyte counts, and consequently higher NLR, indicating a more immunocompromised state than in male patients during the days immediately following surgery for stomach cancer [15]. Based on these results, we hypothesized that female patients have a higher white blood cell count than male patients under similar circumstances, which is why male patients were excluded in this study.

Liu et al. [34] previously showed that a high preoperative NLR was associated with increased tumor size and a high risk of recurrence in differentiated thyroid cancers. In this study, the NLR did not have significant association with the clinicopathological characteristics in PTC patients. But an elevated PLR values (especially in the first to third quartiles) were associated with an increased risk of lateral LNM (Table 3). However, patients in the fourth quartiles (PLR >156.25) had a lower incidence of lateral LNM than those belonging to the second and third quartiles. Seretis et al. [13] have reported similar results, showing a significant association of between a high NLR and thyroid cancer, especially for NLR >2.5, although the third (NLR >2.5 to 3.0) and fourth (NLR >3 to 6.9) quartiles showed lower incidences of thyroid cancer than the first and second. Although further large multicenter studies are required to confirm this association in thyroid cancer patients, our results suggest that there is a weak association between the NLR or PLR and prognosis in thyroid cancer once the NLR or PLR exceeds a certain value. Previous study showed that combination of NLR and PLR value was found to be much more applicable for predicting postoperative survival than patient stratification according to either the NLR or PLR alone in an esophageal squamous cell carcinoma [18]. Therefore we evaluated the usefulness of combination of NLR and PLR for predicting prognostic factor in patients with PTC. Unfortunately, our result showed no significant correlation with prognostic factors in PTC patients.

There were several limitations to our study. First, our study design was retrospective and only Asian patients in single institution were included; hence, our study did not represent the general population. Second, some studies have reported that chemotherapy can normalize an elevated NLR, and that patients with a normalized NLR may have improved outcomes [35,36]. However, our study did not evaluate the changes in NLR and PLR after thyroidectomy, or radioactive iodine therapy. Third, serum CRP levels are not evaluated during routine preoperative laboratory examinations of thyroid cancer patients. Neutrophil and lymphocyte counts may be influenced by infections, inflammation, medication, and other noncancerous conditions [37,38]. As we did not evaluate other medical conditions or medications, our results might be influenced by these confounding factors. Fourth, this study included only female patients with PTC.

Despite these limitations, this study offers some insight on our understanding of the link between preoperative inflammatory marker such as NLR, PLR and clinicopathological characteristics in patients with PTC. To the best of our knowledge, this study was the first study for association between PLR and prognostic factors in patients with PTC.

In conclusion, higher preoperative PLR were associated with...
lateral LNM in patients with PTC. Measurement of the PLR is cost-effective, safe, and readily available. Thus, preoperative PLR may be valuable for predicting adverse clinicopathological outcomes in PTC. More large-scale prospective studies are required to validate our results, before the preoperative NLR or PLR can be used as biomarkers for risk stratification.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This work was supported by clinical research grant from Pusan National University Hospital 2015.

REFERENCES

1. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009;12:223-6.
2. Wang DS, Ren C, Qiu MZ, Luo HY, Wang ZQ, Zhang DS, et al. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumour Biol 2012;33:749-56.
3. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 2010;6:149-63.
4. Kim S, Cho SW, Min HS, Kim KM, Yeom GJ, Kim EY, et al. The expression of tumor-associated macrophages in papillary thyroid carcinoma. Endocrinol Metab (Seoul) 2013;28:192-8.
5. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007;73:215-20.
6. Walsh SR, Cook EJ, Goulter F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005;91:181-4.
7. Malik HZ, Prasad KR, Halazun KJ, Aldoori A, Al-Mukhtar A, Gomez D, et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg 2007;246:806-14.
8. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 2008;34:55-60.
9. Gomez D, Morris-Stiff G, Toogood GJ, Lodge JP, Prasad KR. Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 2008;97:513-8.
10. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009;58:15-23.
11. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 2009;197:466-72.
12. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers 2012;17:216-22.
13. Seretis C, Gourgiotis S, Gemenetzis G, Seretis F, Lagoudianakis E, Dimitrakopoulos G. The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: a pilot study. Am J Surg 2013;205:691-6.
14. Han SW, Kang SY, Kim SK, Youn HJ, Jung SH. Clinical significance of blood neutrophil-to-lymphocyte ratio in patients with papillary thyroid carcinoma. Korean J Endocr Surg 2014;14:184-9.
15. Gwak MS, Choi SJ, Kim JA, Ko JS, Kim TH, Lee SM, et al. Effects of gender on white blood cell populations and neutrophil-lymphocyte ratio following gastrectomy in patients with stomach cancer. J Korean Med Sci 2007;22 Suppl:S104-8.
16. Molloy EJ, O’Neill AJ, Grantham JJ, Sheridan-Pereira M, Fitzpatrick JM, Webb DW, et al. Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood 2003;102:2653-9.
17. Ito Y, Miyauchi A, Kihara M, Kobayashi K, Miya A. Prognostic values of clinical lymph node metastasis and macroscopic extrathyroid extension in papillary thyroid carcinoma. Endocr J 2014;61:745-50.
18. Feng JF, Huang Y, Liu JS. Combination of neutrophil lymphocyte ratio and platelet lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma. Onco Targets Ther 2013;6:1605-
12. Edge SB; American Joint Committee on Cancer; American Cancer Society. AJCC cancer staging handbook: from the AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

19. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg 2010;200:197-203.

20. Azuma T, Matayoshi Y, Odani K, Sato Y, Sato Y, Nagase Y, et al. Preoperative neutrophil-lymphocyte ratio as an independent prognostic marker for patients with upper urinary tract urothelial carcinoma. Clin Genitourin Cancer 2013;11:337-41.

21. Di Carlo E, Forni G, Musiani P. Neutrophils in the antitumoral immune response. Chem Immunol Allergy 2003;83:182-203.

22. McCourt M, Wang JH, Sookhai S, Redmond HP. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg 1999;134:1325-31.

23. Jabłońska E, Kiluk M, Markiewicz W, Piotrowski L, Grabowska Z, Jabłonski J. TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Arch Immunol Ther Exp (Warsz) 2001;49:63-9.

24. Schaidter H, Oka M, Bogenrieder T, Nesbit M, Satyamoorthy K, Berking C, et al. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer 2003;103:335-43.

25. Shamamian P, Schwartz JD, Pocock BJ, Monea S, Whitting D, Marcus SG, et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol 2001;189:197-206.

28. Scapini P, Nesi L, Morini M, Tanghetti E, Belleri M, Noonan D, et al. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol 2002;168:5798-804.

29. Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002;22:913-22.

30. Sharma R, Zucknick M, London R, Kacevska M, Liddle C, Clarke SJ. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer 2008;7:331-7.

31. Sharma R, Hook J, Kumar M, Gabra H. Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer 2008;44:251-6.

32. Schmidt-Selk S, Langsenlehner U, Thurner EM, Stojakovic T, Pichler M, Gerger A, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br J Cancer 2014;110:2524-30.

33. Wang D, Yang JX, Cao DY, Wan XR, Feng FZ, Huang HF, et al. Preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios as independent predictors of cervical stromal involvement in surgically treated endometrioid adenocarcinoma. Onco Targets Ther 2013;6:211-6.

34. Liu CL, Lee JJ, Liu TP, Chang YC, Hsu YC, Cheng SP. Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. J Surg Oncol 2013;107:493-7.

35. Kao SC, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010;16:5805-13.

36. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 2011;104:1288-95.

37. Azab B, Jaglall N, Atallah JP, Lamet A, Raja-Surya V, Farah B, et al. Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis. Pancreatology 2011;11:445-52.

38. Park JJ, Jang HJ, Oh IY, Yoon CH, Suh JW, Cho YS, et al. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2013;111:636-42.